We're at the forefront of pain management treatment

We focus on novel targets that are outside of the opioid pathway and are non-addictive. For chronic inflammatory pain, our compounds target downstream in a commercially validated pain pathway which may provide for better efficacy and an enhanced safety profile.

Additionally, for chronic neuropathic pain, our compounds target central sensitization and synaptic plasticity that may have an enhanced tolerability profile over currently administered therapeutics.